Overview
It is a single-center, prospective study, which will be conducted in a tertiary academic hospital (Prince of Wales Hospital). All subjects will undergo a paired examination of HemoPill® acute capsule and oesophago-gastro-duodenoscopy (OGD).
Description
It is a single-center, prospective study, which will be conducted in a tertiary academic hospital (Prince of Wales Hospital). All subjects will undergo a paired examination of HemoPill® acute capsule and oesophago-gastro-duodenoscopy (OGD).
Eligibility
Inclusion Criteria:
Subjects are eligible if:
- They have symptoms and signs of suspected UGIB (melena, per rectal bleeding, coffee ground vomiting, history of hematemesis);
- They will undergo OGD within 24 hours;
- Written consent obtained.
Exclusion Criteria:
Subjects will be excluded from the study if they have any of the followings:
- Contraindications for OGD (e.g. respiratory failure, suspected perforation);
- Contraindications for capsule endoscopy (e.g. known gastrointestinal obstruction or stricture, severe dysphagia, impaired consciousness);
- Cardiac pacemaker or implanted electromedical devices;
- History of gastrectomy or bowel resection;
- Active ongoing fresh hematemesis;
- Unstable hemodynamics despite adequate resuscitation;
- Advanced comorbidities (defined as American Society of Anesthesiologists grade 4 or above);
- Pregnancy.